Ovid Therapeutics (OVID) Change in Acquisitions & Divestments (2018 - 2026)

Ovid Therapeutics (OVID) has reported Change in Acquisitions & Divestments for 7 consecutive years, with $16.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Acquisitions & Divestments fell 5.88% year-over-year to $16.0 million; the trailing twelve-month figure through Jun 2026 stood at $41.0 million (down 45.33% YoY), and the FY2025 full-year result was $42.0 million, down 67.19% from the prior year.
• Change in Acquisitions & Divestments climbed to $16.0 million in Q2 2026 per OVID's latest filing, from $10.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $60.0 million in Q4 2022 and bottomed at $5.0 million in Q4 2025.
• Historically, Change in Acquisitions & Divestments has averaged $25.4 million across 5 years, with a median of $21.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Change in Acquisitions & Divestments soared 280.0% in 2024, then sank 86.84% in 2025.
• Over 5 years, Change in Acquisitions & Divestments stood at $60.0 million in 2022, then slumped by 83.33% to $10.0 million in 2023, then jumped by 280.0% to $38.0 million in 2024, then tumbled by 86.84% to $5.0 million in 2025, then soared by 220.0% to $16.0 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $16.0 million, $10.0 million, and $5.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.